OKYO Pharma Limited (OKYO)
|52 Week Range||0.92-7.0|
|1y Target Est||-|
|DCF Unlevered||OKYO DCF ->|
|DCF Levered||OKYO LDCF ->|
|Debt / Equity||-107.88%||Sell|
Upgrades & Downgrades
Latest OKYO news
OKYO Pharma announces share offering
13 September 2023
OKYO Pharma Ltd (NASDAQ:OKYO) has announced a public offering of its shares with the net proceeds to fund the clinical development of its product candidates and for general corporate purposes and work...
OKYO Pharma completes enrollment in Phase 2 clinical trial to treat dry eye disease
8 September 2023
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has completed full enrollment of patients in the randomized portion of the Phase 2 multi-center, double-masked, placebo-controlled clinical trial of top...
OKYO Pharma dry eye disease trial reaches enrollment milestone; topline data expected by year-end
30 August 2023
OKYO Pharma Ltd (NASDAQ:OKYO) said it has enrolled 90% of patients in its 240-patient Phase 2 evaluating topical ocular OK-101 to treat dry eye disease (DED). Full enrollment is anticipated to be comp...
Trading Penny Stocks This Week? 4 To Watch With Big News
29 August 2023
Are you trading penny stocks this week? Chances are that if you're reading this article, you have some intention of finding more info on cheap stocks.
OKYO Pharma expects large enrolment in dry eye trial patients
15 August 2023
OKYO Pharma Ltd (NASDAQ:OKYO) has announced it expects to see an increase in the number of patients enrolling on its dry eye disease clinical trial this summer. Having announced the testing of drug OK...
OKYO Pharma makes good progress with flagship OK-101 drug as it wraps up its 2023 financial year
15 August 2023
OKYO Pharma Ltd (NASDAQ:OKYO) told investors it expects to see considerable enrollments of patients in the ongoing trial of its flagship drug OK-101 to treat dry eye disease (DED) this summer and is o...
Why Is OKYO Pharma (OKYO) Stock Down 19% Today?
1 August 2023
OKYO Pharma (NASDAQ: OKYO ) stock is falling on Tuesday even after the biopharmaceutical company withdrew a public offering. According to a press release from the company, it decided to withdraw this ...
OKYO Pharma inks collaboration with Tufts Medical Center
28 July 2023
OKYO Pharma Ltd (NASDAQ:OKYO) has revealed a new partnership with Tufts Medical Center to conduct an open-label clinical trial to assess the efficacy and safety of OK-101 in treating patients with neu...
OKYO Pharma begins OK-101 phase 2 dosing
6 June 2023
OKYO Pharma said patients are being dosed in a randomise portion of a phase 2 trial for its OK-101 drug to treat dry eye disease (DED). The ophthalmology-focused biopharmaceutical company said in a st...